Publications
5539 Results
- Journal / Conference
- Hematology Oncology Vol 41 Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
- Year
- 2023
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1918
S1918: Phase II/III study of R-miniCHOP +/- oral azacitidine in participants age 75 years or older with diffuse large B cell and related lymphomas
- Journal / Conference
- American Journal of Human Genetics Jul 6;110(7):1200-1206
- Year
- 2023
- Research Committee(s)
- Cancer Control and Prevention and Epidemiology
- PMID
- PMID37292833
- PMC
- PMC10246022
- Study Number(s)
- S0000, SWOG-9217
Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry
- Journal / Conference
- ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA), poster
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1613
A Randomized Phase 2 Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification: SWOG S1613
- Journal / Conference
- Clinical Cancer Research May 26;CCR-22-3947. doi: 10.1158/1078-0432.CCR-22-3947. Online ahead of print
- Year
- 2023
- Research Committee(s)
- Lung
- PMID
- PMID37233987
- PMC
- PMC10526968
- Study Number(s)
- S1507
Phase II study of docetaxel and trametinib in patients with G12C and non-G12C KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT)
- Journal / Conference
- JCO Clinical Cancer Informatics Apr;7:e2200165
- Year
- 2023
- Research Committee(s)
- Lung
- PMID
- PMID37084329
- PMC
- PMC10281446
- Study Number(s)
- S1400I
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)
- Journal / Conference
- Blood Advances Sep 12;7(17):5082-5090
- Year
- 2023
- Research Committee(s)
- Lymphoma
- PMID
- PMID37379264
- PMC
- PMC10471938
- Study Number(s)
- S0016
Subclonal TP53 mutation are frequent and predict resistance to radio-immunotherapy in follicular lymphoma
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 9035); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Lung
- Study Number(s)
- LUNGMAP
The effect of ctDNA Tumor Fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS9143); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), tip, poster session
- Year
- 2023
- Research Committee(s)
- Lung
- Study Number(s)
- S1900E
ECOG-ACRIN LUNG-MAP S1900E Substudy (NCT04625647): A Phase II Study of Sotorasib in Participants (Pts) With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous (Non-sq) Non-Small Cell Lung Cancer (NSCLC)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 8504); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
- Year
- 2023
- Research Committee(s)
- Lung
- Study Number(s)
- S1929
SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab (A) Versus Atezolizumab + Talazoparib (AT) in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 12003); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
- Year
- 2023
- Research Committee(s)
- Symptom Control and Quality of Life
- Study Number(s)
- S1714